Stay away from concomitant utilization of tucatinib with CYP3A substrates, in which negligible concentration improvements may possibly result in serious or lifestyle-threatening toxicities. If unavoidable, decrease CYP3A substrate dose As outlined by solution labeling. Akutt og alvorlig allergisk